Scribe Therapeutics Inc., a molecular engineering company pioneering a CRISPR by Design™ platform for genetic medicine, today announced it will participate in four upcoming conferences.

Scribe co-founder and CEO Benjamin Oakes will participate in a fireside chat at 12 p.m. ET on Monday, Nov. 21, 2022, at the BMO Capital Markets Epigenome Editing Event.

The following week, the Scribe management team will participate in the virtual Evercore ISI HealthCONx Conference taking place from Tuesday, Nov. 29 to Thursday, Dec. 1, 2022.

Scribe Chief Financial Officer David Parrot will present at the Piper Sandler Annual Healthcare Conference at 10:50 a.m. ET on Tuesday, Nov. 29, 2022 in New York, NY.

Scribe co-founder and Vice President of Platform Brett Staahl will present at the CRISPR 2.0 Summit in Boston, Mass. His presentation titled “Honing Novel Gene Editing Tools for Improved Activity, Specificity and Deliverability” will take place during the “Strategies to Refine CRISPR Tools” session at 8 a.m. ET on Wednesday, Nov. 30, 2022.

About Scribe Therapeutics

Scribe Therapeutics is a molecular engineering company focused on creating best-in-class in vivo therapies that permanently treat the underlying cause of disease. Founded by CRISPR inventors and leading molecular engineers Benjamin Oakes, Brett Staahl, David Savage, and Jennifer Doudna, Scribe is overcoming the limitations of current genome editing technologies by developing custom engineered enzymes and delivery modalities as part of a proprietary, evergreen CRISPR by Design™ platform for genetic medicine. The company is backed by leading individual and institutional investors including Andreessen Horowitz, Avoro Ventures and Avoro Capital Advisors, OrbiMed Advisors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., funds managed by Wellington Management, RA Capital Management, and Menlo Ventures. To learn more about Scribe’s mission to engineer the future of genetic medicine, visit www.scribetx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005481/en/